Thierry Bernard
Known title: DirectorCIK: 0001815490
Associated companies
this person other insiders at BRKRP
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Transaction History
| BRKRP | ▲ Buy | Grant | 2,886 | $0 | 5/15/2026 | View on chart |
| NEOG | ▲ Buy | Grant | 19,769 | $120K | 10/23/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 5,620 | $81K | 11/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BRKR risk highlighted in recent market analysis
A recent article discusses why Bruker (BRKR) is considered risky, suggesting alternative stocks. This commentary focuses on the parent company's common stock, which may influence sentiment for its preferred shares. The preferred stock has a low dividend yield and trades within a wide 52-week range.
BRKR risk highlighted in recent market analysis. A recent article discusses why Bruker (BRKR) is considered risky, suggesting alternative stocks. This commentary focuses on the parent company's common stock, which may influence sentiment for its preferred shares. The preferred stock has a low dividend yield and trades within a wide 52-week range.